Caixin
Caixin Global – Latest China News & Headlines

Home >

ABOUT US

CX Tech is Caixin Global's real-time tech news portal, featuring 24-hour news, short-form analysis, and roundups from business and tech media in China.

TRENDING
TikTok Owner ByteDance Increasing Indian Operations: Reports
Xiaomi Maintains Lead in India’s Smartphone Market, But Chinese Peers Catch Up
Chinese Online Grocery Operation Dada Seeks $280 Million in U.S. IPO
LATEST
Chinese Chipmaker SMIC Eyes $2.8 Billion From Shanghai Listing
Trending in China: Taiwan Pop Star Jay Chou Debuts on Mainland Social Media
Bilibili to Launch Satellite for Science Education Content
BYD Batteries to Power Ford Hybrid
Trending in China: Good News For Street Vendors and Lovers of Street Food
TikTok Owner ByteDance Increasing Indian Operations: Reports
Chinese Online Grocery Operation Dada Seeks $280 Million in U.S. IPO
NetEase Starts $2.6 Billion Hong Kong Secondary Listing
E-Retailer Mogu’s Sales Drop, Even as Livestreaming Makes Big Gains
Xiaomi Maintains Lead in India’s Smartphone Market, But Chinese Peers Catch Up
Didi Self Driving Unit Secures $500 Million in First Funding Round
Trip.com, Nio and Momo Take First-Quarter Revenue Hits
EHang to Trial Heavy Air Cargo Drones
Video Streamer Bilibili Plans to Issue $650 Million in Convertible Bonds
Revenue Growth, R&D Spending Slow for China Internet Majors
Tencent to Invest $70 Billion in ‘New Infrastructure’ Supporting AI and Cloud Computing
BYD Semiconductor Unit Gets Charged with Major New Investment
Hong Kong, Singapore Welcome Back Transit Travelers
China Making Headway on Its First Long-Haul Jetliner: Reports
Stay-at-Home Blues During Covid-19 Turbocharges Livestreaming Game Streamer DouYu
Biotech Firm Viva to Raise Up to HK$1.5 Billion in Hong Kong IPO

By Liu Yanfei and Han Wei / Apr 26, 2019 02:56 AM / Business & Tech

Photo: Bloomberg

Photo: Bloomberg

Another China-based biotech company will debut on the Hong Kong market.

Leading contract drug researcher Viva Biotech Holdings started its initial public offering share sales in Hong Kong Thursday aiming to raise between HK$1.18 billion and HK$1.52 billion ($150 million to $194 million).

Shanghai-based Viva planned to sell 345 million shares at a price range between HK$3.42 and HK$4.41 a share. The offering opened at 9 a.m. Thursday and will close at noon Tuesday in Hong Kong.

Established in 2008, Viva provides structure-based drug-discovery services to biotechnology and pharmaceutical customers. Its clients include nine of the world’s top 10 pharmaceutical companies, according to Viva’s prospectus. In 2018, Viva said it booked 210 million yuan ($31 million) of revenue, up 41.7% from the previous year, and 90.6 million yuan of net profit, up 18.7%.

Three cornerstone investors — Sinopharm Capital and two funds controlled by Shenzhen GTJA Investment Group ― subscribed for a combined 26% of Viva’s offering.

Viva’s stock will debut on the Hong Kong exchange May 9. China International Capital Corp. Hong Kong Securities Ltd. is the sole sponsor of the offering.

Related: Hong Kong Smiles on Biotech, Lowballs Club Med in Latest IPOs

Share this article
Open WeChat and scan the QR code